0.9353
전일 마감가:
$0.9393
열려 있는:
$0.9277
하루 거래량:
31,002
Relative Volume:
0.01
시가총액:
$966.68K
수익:
-
순이익/손실:
$-6.90M
주가수익비율:
-0.0667
EPS:
-14.0152
순현금흐름:
$-6.65M
1주 성능:
-10.92%
1개월 성능:
-19.37%
6개월 성능:
-53.70%
1년 성능:
-82.55%
Bluejay Diagnostics Inc Stock (BJDX) Company Profile
명칭
Bluejay Diagnostics Inc
전화
(978) 631-0152
주소
360 MASSACHUSETTS AVENUE, SUITE 203, ACTON
Compare BJDX vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
BJDX
Bluejay Diagnostics Inc
|
0.9343 | 993.43K | 0 | -6.90M | -6.65M | -14.02 |
|
ABT
Abbott Laboratories
|
116.00 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
SYK
Stryker Corp
|
330.14 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
93.19 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
BSX
Boston Scientific Corp
|
50.44 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
90.25 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bluejay Diagnostics Inc 주식(BJDX)의 최신 뉴스
Bluejay (BJDX) Session-Level Review: Loses 4.90% to Close at $0.97 at the Close; Reference Levels: the Session Ends Within the Reported Technical Boundaries for the Current SessionGrowth ETF - Vinanet
Bluejay Diagnostics (BJDX) links director options to FDA nod - Stock Titan
Bluejay Diagnostics (BJDX) links director’s 100K options to FDA clearance - Stock Titan
Bluejay Diagnostics (BJDX) ties director’s options to FDA device clearance - Stock Titan
Bluejay Diagnostics (NASDAQ: BJDX) insider updates share holdings - Stock Titan
Bluejay Diagnostics (NASDAQ: BJDX) ties director options to FDA clearance - Stock Titan
Armistice Capital discloses 9.99% Bluejay Diagnostics (BJDX) position in Schedule 13G - Stock Titan
Bluejay Diagnostics (BJDX) investor group discloses 9.99% ownership with warrants - Stock Titan
Form 8K Bluejay Diagnostics Inc For: 13 August By Investing.com - Investing.com Nigeria
Bluejay Advances Symphony Platform, Strengthens Cash Position - TipRanks
Form 8K Bluejay Diagnostics Inc For: 13 August - Investing.com India
Bluejay Diagnostics Q2 Results: EPS loss narrows 80% YoY to $(1.12) - scanx.trade
Bluejay Diagnostics completes enrollment in sepsis test study - Investing.com
Bluejay Diagnostics completes enrollment in sepsis test study By Investing.com - Investing.com Australia
Bluejay Diagnostics Completes Enrollment in SYMON-II Pivotal Study, Advances Toward 510(k) Submission and Commercialization - quiverquant.com
Bluejay completes 750-patient study enrollment for Symphony IL-6 - Stock Titan
Bluejay Diagnostics, Inc. Q2 2026: Net loss $(2.32M), EPS $(1.12) — 10-Q Summary - TradingView
Bluejay Diagnostics (BJDX) warns on going concern and Nasdaq listing risk - Stock Titan
Bluejay Diagnostics Inc (BJDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bluejay Diagnostics Inc (BJDX) Stock News Today - tradingkey.com
Why Are Traders Watching Bluejay Diagnostics (NASDAQ:BJDX) This Week? - Kalkine Media
Bullish Volume: RITR, IGC, BJDX, CISS Lead Active Sub-$1 Stocks to Watch - Barchart.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
BJDX Stock Dips As Pivotal Sepsis Study Finishes Early - StocksToTrade
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
BJDX Stock Dips As Pivotal Sepsis Trial Finishes Enrollment Early - StocksToTrade
Bluejay Diagnostics (NASDAQ:BJDX) soars 47% premarket; warrant financing still subject to conditions - TechStock²
Trending Stocks Today | Julong Soars 42.47% Pre-Market - Moomoo
Ready for the party🤓 - Moomoo
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Bluejay Diagnostics Stock Short Interest Rises to 58.61% - Quiver Quantitative
BJDX Q4 2023 Earnings: Significant Earnings Miss as Bluejay Diagnostics Reports Higher-Than-Expected LossRevenue Inflection Point - Vinanet
Bluejay Diagnostics Inc (BJDX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BJDX|Bluejay Diagnostics Inc|Price:1.070|Chg%:-0.080 - TradingKey
Bluejay Diagnostics Inc (BJDX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bluejay Diagnostics Inc (BJDX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bluejay Diagnostics Inc (BJDX) Institutional Confidence - TradingKey
Bluejay Diagnostics Inc (BJDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bluejay Diagnostics Inc (BJDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bluejay Diagnostics Inc (BJDX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bluejay Diagnostics Inc (BJDX) Cash Flow - TradingKey
Bluejay Diagnostics Inc (BJDX) Balance Sheet - TradingKey
BJDX|Bluejay Diagnostics Inc|Price:1.055|Chg%:-0.005 - TradingKey
Bluejay Diagnostics Inc (BJDX) Income Statement - TradingKey
Bluejay Diagnostics, Inc. Revenue Breakdown – NASDAQ:BJDX - TradingView
BJDX Q4 2023 Earnings: Significant EPS Miss Amid Pre‑Revenue Development StagePre-Earnings Setup - Vinanet
Bluejay Diagnostics Inc (BJDX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bluejay Diagnostics initial beneficial ownership statement names Bank of America as 10% owner - Bitget
Form 4 Bluejay Diagnostics Inc For: 22 July By Investing.com - Investing.com South Africa
Bluejay Diagnostics Completes Enrollment in SYMON-II Sepsis Study - TipRanks
Bank of America drops below 10% stake in Bluejay Diagnostics, Inc. (BJDX) - Stock Titan
Bluejay Diagnostics Inc (BJDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):